Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01203410 · ClinicalTrials.gov registry record

Prediction of Jaundice in Term Infants

A clinical trial, sponsored by NICHD Neonatal Research Network.

Completed
Registry status
535
Enrollment target

NCT01203410: Completed study, sponsored by NICHD Neonatal Research Network.

NCT01203410 is a clinical trial that has completed, run by NICHD Neonatal Research Network. The registered enrollment target is 535 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01203410 has completed, sponsored by NICHD Neonatal Research Network.

COMPLETED
Registry status
535 participants
Enrollment target

Study Summary

The objective of this study was to describe total bilirubin production in healthy term infants as a means of understanding the differences in jaundice pigment production associated with various common clinical circumstances.

Primary Outcome

An index of bilirubin production

Trial Details

FieldValue
Enrollment Target 535 participants
Start Date 1991-11
Est. Completion 1992-11
NICHD Neonatal Research Network

61 total trials

What the finished NCT01203410 record still lists

NCT01203410 is an observational study that tracks outcomes without assigning an intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01203410 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01203410 about?

NCT01203410 is a clinical study titled "Prediction of Jaundice in Term Infants". The objective of this study was to describe total bilirubin production in healthy term infants as a means of understanding the differences in jaundice pigment production associated with various common clinical circumstances.

What is the current status of trial NCT01203410?

This trial is currently completed. The enrollment target is 535 participants. The study started on 1991-11. Estimated completion is 1992-11.

Who is sponsoring clinical trial NCT01203410?

This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05614739 · 535 participants · Phase 1

    FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

  • NCT07091617 · 535 participants · NA

    Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

  • NCT04910685 · 534 participants · Phase 2

    (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

  • NCT06128551 · 534 participants · Phase 1

    Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01203410, the US trial registry maintained by the National Library of Medicine. NCT01203410 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.